β€’
Aug 31, 2020

AngioDynamics Q1 2021 Earnings Report

AngioDynamics reported a net sales increase of 6.3% compared to the prior-year quarter, with a GAAP loss per share of $0.11 and adjusted earnings per share of $0.02.

Key Takeaways

AngioDynamics reported a strong first quarter with net sales of $70.2 million, a 6.3% increase compared to the prior-year quarter. The company's gross margin was 50.9%, and they reported a GAAP loss per share of $0.11 and adjusted earnings per share of $0.02. They expect fiscal year 2021 net sales between $278 and $284 million and fiscal year 2021 adjusted earnings per share between $0.00 and $0.05.

Net sales increased by 6.3% to $70.2 million compared to the prior-year quarter, including a $5.2 million order from the UK's National Health Service (NHS).

Gross margin decreased to 50.9%, a decline of 700 basis points year over year.

GAAP loss per share was $0.11, while adjusted earnings per share were $0.02.

Cash and cash equivalents were $47.9 million as of August 31, 2020, compared to $54.4 million on May 31, 2020.

Total Revenue
$70.2M
Previous year: $66M
+6.3%
EPS
$0.02
Previous year: $0.08
-75.0%
Gross Margin
50.9%
Previous year: 57.9%
-12.1%
Gross Profit
$35.8M
Previous year: $38.2M
-6.4%
Cash and Equivalents
$47.9M
Previous year: $83.6M
-42.7%
Free Cash Flow
-$7.25M
Previous year: -$7.93M
-8.5%
Total Assets
$584M
Previous year: $690M
-15.4%

AngioDynamics

AngioDynamics

AngioDynamics Revenue by Geographic Location

Forward Guidance

The Company expects fiscal year 2021 net sales to be in the range of $278 to $284 million and fiscal year 2021 adjusted earnings per share to be in the range of $0.00 to $0.05.

Revenue & Expenses

Visualization of income flow from segment revenue to net income